Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them

CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.

The portfolio includes one granted U.S. patent and 19 pending applications filed in the United States, Australia, Canada, China, Europe, Japan, and New Zealand. All patents and applications are solely owned by Decoy.

"Our IP position has grown alongside the science," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "The early filings protected our first conjugates. The newer families protect the engineered sequences our platform now designs, the methods we use to make them, and the platform itself. That progression is one of the clearest external record of how far the technology has come."

Pending Applications

Granted patent. U.S. Patent No. 12,226,474, "Methods and Compositions for Treating Infections," claims antiviral peptide conjugates comprised of one or more viral spike protein sequences that include D-amino acids.

Manufacturing. "Methods for Making Peptide Conjugates and the Product Made Therefrom" is directed to automated flow peptide synthesis methods and linker chemistries applied to Decoy antiviral peptide conjugates. It is Decoy's most broadly filed family, pending in six jurisdictions outside the United States.

Engineered D-MAVs. "New Antiviral Therapeutic Peptides, Conjugates and Methods of Use Thereof" is directed to compounds designed against conserved features of class I viral fusion proteins, extending beyond wild-type peptide sequences. Companion filings are directed to formulations containing these conjugates and the use of said conjugates to interrupt transmission and extends to paramyxoviruses including measles, mumps, human parainfluenza virus, and Nipah.

Platform. Decoy's newest filing, "Method of Designing New Class I Fusion Peptides and Therapeutics Made Thereof," was filed in June 2026 and is directed to the design methods behind the IMP³ACT platform. It has not yet published.